Truist Securities Reiterates Buy Rating on Septerna, Inc.
Truist Securities maintains its Buy rating on Septerna, Inc., setting a price target of $43, a 28.40% upside from the current price.
Key Points
- Truist Securities reiterated its Buy rating on Septerna, Inc. (SEPN) with a target price of $43 on July 1, 2026.
- Truist Securities's $43 price target implies 28.40% upside from Septerna, Inc.'s ($SEPN) current $33.49 share price.
- Shares of Septerna traded near $33.49 on Wednesday, with a market cap of $1.51 billion.
- Insiders including Samira Shaikhly and Bernard Coulie were active in recent stock transactions, while analysts maintain positive ratings.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Truist Securities has reaffirmed its Buy rating on Septerna, Inc. (NasdaqGM: SEPN) as of July 1, 2026, with a price target set at $43. This move reflects continued confidence in the biotechnology company's potential, as shares traded near $33.49 on Wednesday.
Truist Securities vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in Septerna, Inc.
RA Capital Management, L.P. held steady with 6,995,858 shares, valued at approximately $168.1 million. TRV GP V, LLC also maintained its position at 6,215,591 shares, worth about $149.4 million. Driehaus Capital Management LLC reduced its holdings by 413,898 shares, ending with 4,395,572 shares valued at $105.6 million, an 8.6% decrease. Meanwhile, Goldman Sachs Group Inc. increased its stake by 191,298 shares, bringing its total to 2,906,427 shares, valued at about $69.8 million, marking a 7% increase.
Septerna, Inc. Stock Down 13.9%
On Wednesday, shares of Septerna, Inc. traded near $33.49. The company boasts a market capitalization of approximately $1.51 billion. Septerna is not currently profitable, leading to no meaningful P/E ratio. The stock's 52-week range is between $10.30 and $37.99, with a 50-day moving average of $29.11 and a 200-day moving average of $25.41. The company maintains a solid financial position with a current ratio of 4.71 and a quick ratio of 4.63.
$SEPN price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Septerna, Inc. reported revenue of $72.3 million, showing a robust growth rate of 120.11%. Despite this growth, the company posted a net margin of -49.88% and a return on equity of -9.26%. The next earnings report is anticipated on May 11, 2026.
Insider Buying and Selling at Septerna, Inc.
Recent insider activity includes multiple transactions by Chief People Officer Samira Shaikhly, who executed both planned and unplanned sales and purchases on June 29, 2026. Bernard Coulie and Alan Ezekowitz each purchased 15,000 shares on June 26, 2026. These transactions reflect ongoing insider engagement with the company's stock.
Analysts Set New Price Targets
On July 1, 2026, Truist Securities maintained its Buy rating on Septerna, Inc. with a price target of $43. Previously, on June 8, 2026, Raymond James also reaffirmed its Buy rating, setting a target at $53. With nine analysts offering opinions, the consensus rating remains a strong buy, with an average target price of $44.89.
About Septerna, Inc.
Septerna, Inc. is a biotechnology firm based in South San Francisco, California. The company focuses on discovering and developing oral small molecule therapies targeting G protein-coupled receptors (GPCRs) for various conditions, including endocrinology, immunology, and metabolic diseases. Under the leadership of CEO Dr. Jeffrey T. Finer, the company collaborates with global partners like Novo Nordisk to advance its therapeutic programs.
Bottom Line
Truist Securities' reiterated Buy rating and $43 price target for Septerna, Inc. underscores ongoing analyst confidence in the company's growth prospects. Septerna's recent insider activity and strong institutional interest highlight its appeal, though investors should note that 13F filings and analyst ratings are backward-looking and may not reflect the most current positioning.
Get Septerna, Inc. alerts
New 13F filings, insider trades, and analyst moves on $SEPN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.